Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 14/20 | 0.51 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18436503 | 0.84 | BRD4 (0.61) | BRD4BRD9BRD7L3MBTL1 | |
| SCHEMBL24556526 | 0.79 | BRD4 (0.51) | BRD4BRD9BRD7POLBL3MBTL1 | |
| SCHEMBL19869850 | 0.79 | BRD4 (0.51) | BRD4BRD9BRD7L3MBTL1CYP1A2 | |
| SCHEMBL147830 | 0.77 | BRD4 (0.51) | BRD4BRD9BRD7L3MBTL1CYP1A2 | |
| SCHEMBL17559093 | 0.71 | KAT2B (0.47) | ALDH1A1HPGD | |
| SCHEMBL19377004 | 0.71 | KAT2B (0.47) | BRD4GAAHPGD | |
| SCHEMBL26262798 | 0.70 | BRD4 (0.45) | BRD4BRD9BRD7L3MBTL1CYP1A2 | |
| SCHEMBL24556465 | 0.70 | NQO2 (0.49) | BRD4BRD9BRD7POLBGAA | |
| SCHEMBL147301 | 0.70 | BRD4 (0.67) | BRD4BRD9BRD7POLBL3MBTL1 | |
| SCHEMBL10005836 | 0.68 | BRD4 (0.43) | BRD4BRD9BRD7L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| EP-3124482-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | SMO, GLI1, SHH | BRD4 24/4885BRD9 205/4885BRD7 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.